Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.
Somaieh HedayatLuciano CascioneDavid CunninghamHeinz-Josef LenzAndrea LampisJens Claus HahneNina TunariuSung Pil HongSilvia MarchettiKhurum KhanElisa FontanaValentina AngerilliMia DelrieuxDaniel Nava RodriguesLetizia ProcaccioSheela RaoDavid WatkinsNaureen StarlingIan ChauChiara BraconiNicos FotiadisRuwaida BegumNaomi Jayne GuppyLouise HowellMelanie ValentiScott CribbesBernadett KolozsvariVladimir KirkinSara LonardiMichele GhidiniRodolfo PassalacquaRaghad ElghadiLuca MagnaniDavid James PinatoFederica Di MaggioFilippo GhelardiElisa SottotettiGuglielmo VeterePaolo CiracìGeorgios VlachogiannisFilippo PietrantonioChiara CremoliniAlessio CortelliniFotios LoupakisAngelo Paolo Dei TosNicola ValeriPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Our results identify MIR652-3p as a potential biomarker and as a driver of cell and non-cell-autonomous mechanisms of resistance to regorafenib.